KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Bristol Myers Squibb (BMY) EBT Margin (2016 - 2025)

Bristol Myers Squibb (BMY) has disclosed EBT Margin for 17 consecutive years, with 11.76% as the latest value for Q4 2025.

  • On a quarterly basis, EBT Margin rose 1034.0% to 11.76% in Q4 2025 year-over-year; TTM through Dec 2025 was 19.36%, a 3670.0% increase, with the full-year FY2025 number at 19.36%, up 3670.0% from a year prior.
  • EBT Margin was 11.76% for Q4 2025 at Bristol Myers Squibb, down from 25.48% in the prior quarter.
  • In the past five years, EBT Margin ranged from a high of 26.52% in Q1 2025 to a low of 97.06% in Q1 2024.
  • A 5-year average of 10.97% and a median of 15.9% in 2021 define the central range for EBT Margin.
  • Peak YoY movement for EBT Margin: tumbled -12149bps in 2024, then soared 12358bps in 2025.
  • Bristol Myers Squibb's EBT Margin stood at 15.5% in 2021, then increased by 5bps to 16.3% in 2022, then dropped by -11bps to 14.59% in 2023, then plummeted by -90bps to 1.42% in 2024, then skyrocketed by 729bps to 11.76% in 2025.
  • Per Business Quant, the three most recent readings for BMY's EBT Margin are 11.76% (Q4 2025), 25.48% (Q3 2025), and 14.45% (Q2 2025).